Our first COVID-19 related monoclonal antibodies will be soon available: Ten antibodies specific to SARS-CoV-2 nucleoprotein and two antibodies specific to Spike (RBD) will be launched in 2-3 weeks.

Cat.# 3CV4 Monoclonal anti-SARS-CoV-2 Nucleoprotein
MAbs: NP1503, NP1510, NP1516, NP1517, NP1518, NP1524, NP1525, NP1526, NP1528, NP1529

Cat.# 3CV2 Monoclonal anti-SARS-CoV-2 Spike
MAbs: RBD1106, RBD1125

Please note that these first antibodies will be produced as in vivo products. The same antibodies in recombinant or in vitro formats will be ready in November/December.

Additional clones will become available in the coming weeks as well.

See all our COVID-19 Products